Biohaven EBITDA 2016-2022 | BHVN

Biohaven ebitda from 2016 to 2022. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Biohaven Annual EBITDA
(Millions of US $)
2021 $-679
2020 $-636
2019 $-478
2018 $-220
2017 $-108
2016 $-61
2015 $-10
Biohaven Quarterly EBITDA
(Millions of US $)
2022-09-30 $-76
2022-06-30 $-284
2022-03-31 $-49
2021-12-31 $-217
2021-09-30 $-66
2021-06-30 $-166
2021-03-31 $-231
2020-12-31 $-166
2020-09-30 $-160
2020-06-30 $-159
2020-03-31 $-151
2019-12-31 $-135
2019-09-30 $-90
2019-06-30 $-199
2019-03-31 $-54
2018-12-31 $-48
2018-09-30 $-55
2018-06-30 $-38
2018-03-31 $-83
2017-12-31 $-28
2017-09-30 $-40
2017-06-30 $-25
2017-03-31 $-14
2016-12-31 $-23
2016-09-30 $-28
2016-06-30 $-7
2016-03-31 $-3
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.913B $0.463B
Biohaven Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases principally in the United States. Biohaven Ltd., formerly known as BIOHAVEN PHARM, is based in New Haven, Connecticut.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $140.576B 8.70
GSK (GSK) United Kingdom $75.923B 9.52
Bio-Rad Laboratories (BIO.B) United States $13.735B 32.61
QIAGEN (QGEN) Netherlands $10.436B 19.34
Ginkgo Bioworks Holdings (DNA) United States $2.549B 0.00
Arcus Biosciences (RCUS) United States $1.194B 0.00
Emergent Biosolutions (EBS) United States $0.394B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.152B 0.00
Enzo Biochem (ENZ) United States $0.106B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.012B 0.00